Jul. 13 at 3:48 AM
$SLS those of us paying Know the SLS009 P2 Expansion Results are much better than needed for Approval.
- Fda is reviewing a large data set, 160+ SLS009 patients, and recent topline P2 Expansion Results - and deliberating whether to conditionally approve 009 for these Desperate, Dying AML-MRC patients who've failed all treatments.
- If we see Conditional FDA Approval, and we may, the share price will gap up towards the double digits
$10+.
2. IN ADDITION to Registrational GPS RESULTS, We have Topline P2 SLS009 Accelerated Approval news for patients who continue to Survive - The Longer they Live, the better Median OS results will be that can be reported.
- these patients have 2 to 2.5 month Life Expectancy.
// the fact is: we could, and will see 2 massive Trial Results any day now.
